Covered recipient · General Payments record
CURTIS C TAKEMOTO- GENTILE
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,932.39
- Reported across 215 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $718.96 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $227.85 | 11 |
| Lilly USA, LLC | $222.69 | 11 |
| ABBVIE INC. | $175.90 | 9 |
| PFIZER INC. | $49.58 | 2 |
| Teva Pharmaceuticals USA, Inc. | $26.69 | 1 |
| Exact Sciences Corporation | $16.25 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $27.53 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195866 | CMS |
| ABBVIE INC. | $3.93 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195868 | CMS |
| ABBVIE INC. | $2.12 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195870 | CMS |
| ABBVIE INC. | $25.46 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195872 | CMS |
| ABBVIE INC. | $33.81 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195874 | CMS |
| ABBVIE INC. | $26.03 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195876 | CMS |
| ABBVIE INC. | $1.69 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195878 | CMS |
| ABBVIE INC. | $30.87 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195880 | CMS |
| ABBVIE INC. | $24.46 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106195882 | CMS |
| Exact Sciences Corporation | $16.25 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114927112 | CMS |
| Lilly USA, LLC | $26.28 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136121790 | CMS |
| Lilly USA, LLC | $3.14 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136133170 | CMS |
| Lilly USA, LLC | $24.18 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136121788 | CMS |
| Lilly USA, LLC | $24.77 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136133172 | CMS |
| Lilly USA, LLC | $22.20 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136135676 | CMS |
| Lilly USA, LLC | $25.96 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136125911 | CMS |
| Lilly USA, LLC | $20.47 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136125909 | CMS |
| Lilly USA, LLC | $22.64 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136104720 | CMS |
| Lilly USA, LLC | $6.38 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136104718 | CMS |
| Lilly USA, LLC | $24.78 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136114576 | CMS |
| Lilly USA, LLC | $21.89 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136133174 | CMS |
| Novo Nordisk Inc | $23.40 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097826723 | CMS |
| Novo Nordisk Inc | $21.36 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097699712 | CMS |
| Novo Nordisk Inc | $24.86 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096821214 | CMS |
| Novo Nordisk Inc | $24.65 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097514047 | CMS |
| Novo Nordisk Inc | $22.32 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096798454 | CMS |
| Novo Nordisk Inc | $23.76 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097594558 | CMS |
| Novo Nordisk Inc | $17.62 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096680610 | CMS |
| Novo Nordisk Inc | $3.22 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097716035 | CMS |
| Novo Nordisk Inc | $20.16 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097040626 | CMS |
| Novo Nordisk Inc | $20.84 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097114588 | CMS |
| Novo Nordisk Inc | $25.66 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096907821 | CMS |
| PFIZER INC. | $23.00 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131894166 | CMS |
| PFIZER INC. | $26.58 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131226632 | CMS |
| Teva Pharmaceuticals USA, Inc. | $26.69 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151754740 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.